Benchmark Initiates Coverage On Minimed Group with Buy Rating, Announces Price Target of $20

Benzinga Newsdesk www.benzinga.com Neutral 55.6%

Neg 0% Neu 55.6% Pos 0%

Benchmark analyst Bruce Jackson initiates coverage on Minimed Group (NASDAQ:MMED) with a Buy rating and announces Price Target of $20.